Condition: Diffuse Large B Cell Lymphoma Relapsed · Diffuse Large B Cell Lymphoma Refractory · Follicular Lymphoma ( FL) · Sponsor: GenomeFrontier Therapeutics TW Co., Ltd.
This is a Phase I, prospective, dose-finding study to evaluate the safety, persistence, and clinical activity of GF-CART01 in subjects aged 18-70 with relapsed or refractory (R/R) B-cell hematological malignancies and failure of two-line or more standard chemotherapies or auto-hematopoietic stem cell transplantation (HSCT).This study is a traditional 3+3 dose-escalation design to observe dose-limiting toxicity (DLT), establish the maximum tolerated dose(MTD)/recommended phase 2 doses (RP2D), and preliminary efficacy of GF-CART01. RP2D may equal to or lower than MTD
This description comes directly from the study's public registry record.
Howard Cheng · +886-2-2655-8766 · howardcheng@genomefrontier.com
Always discuss trial participation with your own doctor first.
| National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06703892